The Shotlee Journal
Expert insights on GLP-1 medications, peptide therapy, and evidence-based approaches to weight management.
Loading articles...
Showing 9 / 1267 articles
A Savile Row executive reports that the increasing use of weight loss medications is causing substantial changes in the tailoring business. Rapid weight loss among customers necessitates significant alterations or complete remakes of suits. This trend is particularly noticeable among male clients in their 40s and 50s.
Analyses of GLP-1 receptor agonists for weight management show clinically significant weight loss compared to placebo. However, long-term safety and potential side effects remain uncertain. Financial ties influencing study results are also a concern.
New research suggests that a widely prescribed diabetes drug, metformin, might diminish some key advantages of exercise. The study indicated that individuals taking metformin experienced less improvement in blood sugar management and blood vessel performance compared to those who exercised without the medication.
It's common to gain weight in winter due to cold weather, festive treats, and less activity. However, you can manage your weight by staying active, eating healthy, and addressing common causes. Here's how to avoid winter weight gain.
Medical experts are advising Americans using weight loss medications to be aware of the impact on their travel plans during Thanksgiving. With over 33 million people estimated to be on these prescriptions, understanding necessary precautions is crucial. Key considerations include proper storage, documentation, and timing of doses.
The entertainment industry is seeing a trend of slimmer celebrities, leading to discussions about the role of medications like Ozempic. This shift raises questions about evolving beauty standards and body positivity in Hollywood.
WeightWatchers intends to offer Novo Nordisk's oral Wegovy upon potential FDA approval. This strategic move occurs amidst a competitive weight-loss drug market, aiming to provide a convenient alternative to injections. The FDA is also expediting GLP-1 treatments to improve access.
The demand for weight-loss drugs is surging. New medications promise increased effectiveness and easier administration, including oral options. Several pharmaceutical companies are developing improved injectable drugs.
Richard Saynor, CEO of Sandoz, expects biosimilars referencing semaglutide to be available in Canada in early 2026. This projection comes as Novo Nordisk's patent protection for the drug nears its end. Sandoz intends to capitalize on the commercial opportunity as soon as regulatory approval is granted.
